BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment
BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...
Sinocelltech
Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program
China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...
Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...
China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth
A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...
Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the...